Pages

Friday, December 1, 2017

Monthly injections of buprenorphine approved for opioid addiction treatment

From the American Psychiatric Association Psychiatric News Alert on 12/01/17

The Food and Drug Administration (FDA) has approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adults who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. Sublocade is indicated for patients who have been on a stable dose of buprenorphine treatment for a minimum of seven days and is meant to be used as part of a complete treatment program that includes counseling and psychosocial support. 

For more click here.

No comments:

Post a Comment